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product’s value are the economic and humanistic conse-
quences of the new therapy relative to the gold standard.
However, in many circumstances, the patient is unable to
provide an accurate assessment of healthcare resources
consumed or their quality of life and functional status. Re-
searchers have opted for the use of proxies in these in-
stances, under the presumption that a larger sample size in-
creases the power to detect meaningful differences. This
presumption, however, neglects the inaccuracies inherent
in proxy reporting and thus may inhibit the reliability of
the estimates obtained. This workshop will review and
evaluate the use of proxy respondents in the collection of
resource utilization and quality of life data. A critical ex-
amination will be given to their potential influence on study
results. Suggestions for overcoming these issues will also be
presented and discussed. This session is directed at individ-
uals in pharmaceutical firms, contract research organiza-
tions (CROs), and consultant companies responsible for
the design and conduct of pharmacoeconomic evaluations.
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Assessing the impact of disease and the effect of treat-
ment on patient quality of life (QoL) has become of ma-
jor importance both to the pharmaceutical industry and
the medical profession. The last 20 years have seen the
development of a large number of QoL questionnaires,
increasingly being used in clinical trials, with a growing
emphasis on multinational applications. As a result, there
is a continually expanding need for cross-nationally and
cross-culturally valid, reliable and responsive QoL instru-
ments. This course will provide key information and op-
erational solutions to implement health status and QoL
measures in clinical trials. The content of the course will
cover definitions of health status and QoL; types of in-
struments used, including their strengths and weaknesses;
identification of concepts to be measured; and selection
of relevant instruments. The second part of the course
will focus on strategy for instrument development, lin-
guistic validation and psychometric validation, as well as
interpretation guidelines. Participants will acquire a com-
mon baseline understanding of health and QoL evalua-
tions, allowing them to become actively involved in de-
velopment of optimal programs for clinical development
and marketing purposes.
TRACK 4: STUDY METHODS
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An important element in judging the worthiness of a new
drug’s effects is the translation of randomized trial results
to actual clinical practice. A key input is the risk experi-
enced by routinely managed patients. The risk rate is im-
portant, because the relative risk reduction typically esti-
mated in trials only gains meaning when it is applied to
such a reference risk. While the relative risk reduction is
widely believed to be generalizable, the reference risk is not.
In this workshop, an ongoing study, CAPRA (CAPRIE Ac-
tual Practice Rates Analysis) will be used as a case study—
along with other published reports—to examine why con-
sidering information beyond that obtained in a clinical trial
can be critical in assessing the value of a new therapy. The
major reasons practice may diverge from trials, along with
evidence of this fact, will be introduced. The methods for
extending trial results to clinical practice will be demon-
strated and discussed, along with alternative approaches to
estimating actual practice results from clinical trial experi-
ence. The focus will be on the use of epidemiologic studies
and databases such as that from Saskatchewan Health. De-
tails of this analysis of records for 12,931 patients used to
estimate the risk of first subsequent ischemic events (MI, is-
chemic stroke, vascular death) in actual practice will be
shown. The magnitude of the distortion, with special refer-
ence to numbers needed to treat, and the implications for
cost-effectiveness analysis will be presented. All available
information and methods ought to be employed when con-
sidering a new therapy, as it is insufficient to evaluate a new
therapy based on trial results alone.
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Most pharmacoeconomic studies present estimates of the
impact of new treatments on expected lifetime costs and
health outcomes for typical individuals with a given dis-
ease. However, national or local healthcare decision-
makers also need to know what impact the new treat-
ment will have on their annual budgets and on annual
health outcomes for their patient populations. In this
workshop, a method for estimating the population im-
pacts of new treatments is presented. How information
about the impact of a new treatment on individual pa-
tients can be combined with information about the num-
ber and type of patients in the patient population to esti-
